01:02 PM EDT, 05/30/2025 (MT Newswires) -- Cartesian Therapeutics ( RNAC ) said Friday it enrolled the first participant in its phase 3 myasthenia gravis study that will evaluate Descartes-08, the company's lead cell therapy candidate for autoimmune disease.

The study will evaluate Descartes-08 versus placebo given as six once-weekly outpatient infusions without preconditioning chemotherapy in about 100 participants who have acetylcholine receptor autoantibody positive myasthenia gravis, the company said.

The trial's primary endpoint will assess the proportion of participants with an improvement in myasthenia gravis activities of daily living score of at least three points at month four compared with placebo, the company added.

Price: 9.63, Change: -0.37, Percent Change: -3.70